Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial

被引：0
|
作者：
Bhatt, S. P. [1 ]
Rabe, K. F. [2 ]
Hanania, N. A. [3 ]
Vogelmeier, C. F. [4 ]
Bafadhel, M. [5 ]
Christenson, S. A. [6 ]
Papi, A. [7 ]
Singh, D. [8 ]
Laws, E. [9 ]
Akinlade, B. [10 ]
Maloney, J. [10 ]
Lu, X. [9 ]
Bauer, D. [9 ]
Bansal, A. [10 ]
Abdulai, R. M. [11 ]
Robinson, L. B. [11 ]
机构：
[1] Univ Alabama Birmingham, Pulm Allergy & Crit Care Med, Birmingham, AL USA
[2] LungenClin Grosshansdorf GmbH, Grosshansdorf, Germany
[3] Baylor Coll Med, Houston, TX USA
[4] Univ Marburg, Marburg, Germany
[5] Kings Coll London, London, England
[6] Univ Calif San Francisco, San Francisco, CA USA
[7] Univ Ferrara, Resp Unit, Ferrara, Italy
[8] Univ Manchester, Manchester, Lancs, England
[9] Sanofi, Bridgewater, NJ USA
[10] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[11] Sanofi, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7517
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma
    Corren, Jonathan
    Castro, Mario
    O'Riordan, Thomas
    Hanania, Nicola A.
    Pavord, Ian D.
    Quirce, Santiago
    Chipps, Bradley E.
    Wenzel, Sally E.
    Thangavelu, Karthinathan
    Rice, Megan S.
    Harel, Sivan
    Jagerschmidt, Alexandre
    Khan, Asif H.
    Kamat, Siddhesh
    Maroni, Jaman
    Rowe, Paul
    Lu, Yufang
    Amin, Nikhil
    Pirozzi, Gianluca
    Ruddy, Marcella
    Graham, Neil M. H.
    Teper, Ariel
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02): : 516 - 526
  • [22] DUPILUMAB REDUCES BIOMARKERS OF TYPE 2 INFLAMMATION IN CHILDREN WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA
    Bacharier, L.
    Maspero, J.
    Katelaris, C.
    Fiocchi, A.
    Liu, D.
    Lederer, D.
    Hardin, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S33 - S33
  • [23] Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial
    Rabe, Klaus F.
    Celli, Bartolome R.
    Wechsler, Michael E.
    Abdulai, Raolat M.
    Luo, Xiaodong
    Boomsma, Maarten M.
    Staudinger, Heribert
    Horowitz, Julie E.
    Baras, Aris
    Ferreira, Manuel A.
    Ruddy, Marcella K.
    Nivens, Michael C.
    Amin, Nikhil
    Weinreich, David M.
    Yancopoulos, George D.
    Goulaouic, Helene
    LANCET RESPIRATORY MEDICINE, 2021, 9 (11): : 1288 - 1298
  • [24] Efficacy and safety of ustekinumb for the treatment of moderate-to-severe psoriasis: results of a phase 3 trial in Taiwanese and Korean patients
    Youn, Jai-IL
    Tsai, Tsen-Fang
    Song, Michael
    Shen, Yaung-Kaung
    Li, Shu
    Choi, Jee-Ho
    Kim, Kwang-Joong
    Ho, Ji-Chen
    JOURNAL OF DERMATOLOGY, 2010, 37 : 121 - 122
  • [25] Type 2 Biomarkers Associated with Dupilumab Efficacy in Patients with Uncontrolled, Moderate-To-Severe Asthma Enrolled in the Phase 3 Study LIBERTY ASTHMA QUEST
    Wenzel, S. E.
    Pavord, I.
    Zhang, B.
    Maroni, J.
    Rowe, P.
    Hamilton, J. D.
    Swanson, B. N.
    Amin, N.
    Pirozzi, G.
    Graham, N. M.
    Teper, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [26] Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose
    Pavord, Ian D.
    Bourdin, Arnaud
    Papi, Alberto
    Domingo, Christian
    Corren, Jonathan
    Altincatal, Arman
    Radwan, Amr
    Pandit-Abid, Nami
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Laws, Elizabeth
    Lederer, David J.
    Hardin, Megan
    ALLERGY, 2023, 78 (11) : 2921 - 2932
  • [27] Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
    Corren, Jonathan
    Jackson, David J.
    Casale, Thomas B.
    Borish, Larry
    Rabe, Klaus F.
    Busse, William W.
    Maspero, Jorge F.
    Jackson, Daniel J.
    Daizadeh, Nadia
    Altincatal, Arman
    Radwan, Amr
    Khodzhayev, Angela
    Djandji, Michel
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 249 - 260
  • [28] Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial
    Sasson, Jennifer
    Donlan, Alexandra N.
    Ma, Jennie Z.
    Haughey, Heather M.
    Coleman, Rachael
    Nayak, Uma
    Mathers, Amy J.
    Laverdure, Sylvain
    Dewar, Robin
    Jackson, Patrick E. H.
    Heysell, Scott K.
    Sturek, Jeffrey M.
    Petri, William A., Jr.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (08):
  • [29] Dupilumab efficacy in children with uncontrolled, moderate-to-severe type 2 asthma, with and without evidence of allergy, in the phase 3 VOYAGE study
    Papadopoulos, N. G.
    Szefler, S. J.
    Bacharier, L. B.
    Maspero, J. F.
    Domingo, C.
    Daizadeh, N.
    Lederer, D. J.
    Hardin, M.
    Jacob-Nara, J. A.
    Deniz, Y.
    Gall, R.
    Ortiz, B.
    Djandji, M.
    Rowe, P.
    ALLERGY, 2021, 76 : 175 - 176
  • [30] Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
    Bhatt, S.
    Watz, H.
    Rabe, K.
    Hanania, N.
    Vogelmeier, C.
    Cole, J.
    Bafadhel, M.
    Christenson, S.
    Papi, A.
    Singh, D.
    Laws, E.
    Lu, X.
    Bauer, D.
    Mortensen, E.
    Maloney, J.
    Bansal, A.
    Robinson, L.
    Abdulai, R.
    PNEUMOLOGIE, 2024, 78 : S64 - S64
12345